The [US Fabry Disease Market] is experiencing sustained growth, fundamentally driven by powerful demographic and diagnostic trends. The number of diagnosed prevalent cases in the US is growing, driven by two key factors: increased awareness and early diagnosis through expanded newborn screening programs, and an aging population of patients living longer with the disease . The aging population driver provides a foundation for sustained demand, while improved diagnostic capabilities are expanding the addressable patient pool, ensuring the market's continued expansion.

The Aging Patient Population as a Primary Driver

The US has a significant and growing population of diagnosed Fabry disease patients. In 2024, there were approximately 9,200 diagnosed prevalent cases in the US, representing nearly 52% of the total in the 7MM . This population is not static; as treatments like ERT improve life expectancy, patients are aging, leading to an increased need for long-term disease management and chronic care . This demographic trend ensures a sustained and growing demand for therapies across all stages of life.

Improved Diagnostics and Early Detection as a Key Catalyst

Improved diagnostic capabilities are a powerful catalyst for market growth. Expanded newborn screening programs are identifying affected infants earlier than ever before, allowing for prompt initiation of treatment that can prevent irreversible organ damage . Furthermore, increased awareness among clinicians and greater access to genetic testing are leading to the diagnosis of patients with late-onset forms of the disease, which are more common and were often previously missed . This continuous expansion of the diagnosed patient pool is a key driver of market growth.

The Role of a Strong Pipeline

The growing patient population creates an urgent need for more effective and convenient therapies, which is being met by a robust pipeline. The pursuit of gene therapies and oral medications is a direct response to the limitations of current ERTs, aiming to reduce the treatment burden and improve long-term outcomes for this growing patient base .

The Future of Market Drivers

Looking ahead, the [US Fabry Disease Market] will be shaped by the continued interplay of these key drivers. The aging patient population will remain the fundamental source of demand. However, the power of improved diagnostics to expand the patient pool, coupled with innovations in treatment, will define the market's future. The aging population driver will continue to be the market's foundation, but the power of early diagnosis and innovative therapies will drive its evolution and expansion.